Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDGyre Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.08 | -$0.07 | -$0.07 |
| Q2 2026 | 2 | -$0.57 | $0.45 | -$0.06 |
| Q3 2026 | 2 | -$0.40 | $0.26 | -$0.07 |
| Q4 2026 | 1 | -$0.08 | -$0.07 | -$0.08 |
Gyre Therapeutics Inc Earnings Date And Information
Gyre Therapeutics Inc last posted its earnings results on Thursday, May 7th, 2026. The company reported $-0.05 earnings per share for the quarter, topping analysts' consensus estimates of $-0.06 by $0.01. The company had revenue of 22.52 M for the quarter and had revenue of 116.59 M for the year. Gyre Therapeutics Inc has generated $0 earnings per share over the last year ($0.0225 diluted earnings per share) and currently has a price-to-earnings ratio of -105.74. Gyre Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Gyre Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/08/2026 | Q1 2026 | N/A | -$0.10 | N/A | $31.61 M | $22.52 M |
| 03/13/2026 | Q4 2025 | N/A | -$0.02 | N/A | $35.43 M | $37.20 M |
| 11/07/2025 | Q3 2025 | $0.05 | $0.04 | -0.01 | $32.93 M | $30.56 M |
| 08/11/2025 | Q2 2025 | $0.03 | $0.01 | -0.03 | $30.80 M | $26.77 M |
| 05/09/2025 | Q1 2025 | $0.03 | $0.03 | 0 | $28.40 M | $22.06 M |
| 03/17/2025 | Q4 2024 | $0.04 | -$0.19 | -0.23 | $23.50 M | $27.87 M |
| 11/13/2024 | Q3 2024 | N/A | $0.06 | N/A | N/A | $25.49 M |
| 08/13/2024 | Q2 2024 | N/A | $0.04 | N/A | N/A | $25.23 M |
| 03/30/2024 | Q1 2024 | N/A | $0.09 | N/A | N/A | $27.17 M |
| 02/14/2024 | Q4 2023 | N/A | -$0.68 | N/A | N/A | $27.15 M |
| 10/26/2023 | Q3 2023 | -$0.75 | $0.05 | 0.8 | N/A | $32.04 M |
| 08/14/2023 | Q2 2023 | -$0.07 | $0.08 | 0.15 | N/A | $29.33 M |
| 05/15/2023 | Q1 2023 | -$1.05 | $0.08 | 1.13 | N/A | $24.93 M |
| 03/30/2023 | Q4 2022 | -$1.58 | -$0.06 | 1.52 | N/A | $28.48 M |
| 11/14/2022 | Q3 2022 | -$1.50 | -$0.05 | 1.45 | N/A | $29.17 M |
| 08/15/2022 | Q2 2022 | -$3.68 | $0.08 | 3.75 | N/A | $0 |
| 05/09/2022 | Q1 2022 | N/A | $0.08 | N/A | N/A | $794.00 K |
| 03/31/2022 | Q4 2021 | -$6.85 | -$0.65 | 6.2 | N/A | $2.44 M |
| 11/12/2021 | Q3 2021 | N/A | -$0.80 | N/A | N/A | $2.30 M |
| 08/05/2021 | Q2 2021 | N/A | -$0.64 | N/A | N/A | $1.13 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Gyre Therapeutics Inc Earnings: FAQ's
In the previous quarter, Gyre Therapeutics Inc (:GYRE) reported $-0.05 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.06 by $0.01.
The conference call for Gyre Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Gyre Therapeutics Inc's latest earnings report can be read online.
Gyre Therapeutics Inc (:GYRE) has a recorded annual revenue of $116.59 M.
Gyre Therapeutics Inc (:GYRE) has a recorded net income of $5.03 M.Gyre Therapeutics Inc has generated $0.0563 earnings per share over the last four quarters.
Gyre Therapeutics Inc (:GYRE) has a price-to-earnings ratio of -105.74 and price/earnings-to-growth ratio is 0.5.